

Index

- Abdominal pain
 - anthrax-related, 20
 - plague-related, 45, 46, 47, 54
 - in children, 51
 - tularemia-related, 81, 82
 - viral hemorrhagic fever-related, 177, 178
- Abrin, 209
- Abrus precatorius*, 209
- Abscesses
 - botulism-related, 196
 - glanders-related, 115–116
 - melioidosis-related, 114, 115, 119–120
 - pharyngeal, 81
- Acanthamoeba castellanii*, 78
- Acanthamoeba* spp., 107, 109
- Actinobacillus actinomycetemcomitans*, misidentified
 - Francisella tularensis*, 85–86
- Activated charcoal, as ricin poisoning treatment, 213
- Acute inflammatory polyneuropathy (AIPN), 198, 199
- Acute respiratory distress syndrome (ARDS)
 - anthrax-related, 14
 - melioidosis-related, 114
 - plague-related, 46
- Adenosine analogs, 181–182
- Adenovirus infections, infection control precautions for, 228
- Advanced Trauma Life Support (ATLS), 217, 224
- Advisory Committee on Immunization Practices (ACIP), 159–160
- Aerosol dispersal
 - of botulinum toxins, 201
 - of plague, 38–39
 - of smallpox, 156–158
 - of tularemia, 72
- Aerosols, protection against inhalation of, 220
- Aerosol spray devices, 219
- Afghanistan, biological weapon use in, 118
- African National Council, 7
- Airborne precautions, in infection control, 228
- Airborne transmission. *See also* Aerosol dispersal
 - of plague, 60–61
- Alfred P. Murrah Federal Office Building bombing, 39
- American College of Surgeons, 217, 224
- American Indians, 156
- American Media Incorporation (AMI), 7, 8
- Amherst, Jeffery, 156
- Aminoglycosides
 - as glanders treatment, 105
 - as plague treatment, 41
- Aminoquinolones, as plague treatment, 55
- Amoxicillin-clavulanic acid, as melioidosis treatment, 104, 124
- Ampicillin, as plague treatment, 55–56
- Analgesics, as anthrax treatment, 25
- Anaphylaxis, castor beans-related, 211
- Andes virus, 170
- Anemia, melioidosis-related, 114
- Anorexia
 - anthrax-related, 20
 - bubonic plague-related, 45
 - tularemia-related, 82
- Anthrax, 1–35
 - apoplectic, 23, 24
 - as a biological weapon, 4–8, 219
 - Aum Shinrikyo incident, 7
 - classification as Category A biological weapon, 210
 - cost of planning and preparation for, 242–244, 245, 246
 - October 2001 event, 233
 - threats and hoaxes, 8

Anthrax, (*cont.*)

- Bradford Rules for prevention of, 3
- clinical manifestations of, 13–24
 - in autopsy specimens, 29, 21–22
 - cardiovascular symptoms and signs, 3–4, 14–15, 19
 - cutaneous, 4, 14, 25
 - diaphoresis, 15
 - fatigue, 15–16
 - fever, 15
 - gastrointestinal symptoms and signs, 12, 19–20, 22
 - general symptoms and signs, 3–4, 15–17
 - neurological symptoms and signs, 15–16, 18–19, 23
 - respiratory symptoms and signs, 12, 13, 14, 17–18, 23
- comparison with ricin, 210–211
- cutaneous, 4, 14
 - treatment of, 25
- dispersion through the postal system, 7, 80, 225
- epidemics of, 1
- etiologic agent of (*Bacillus anthracis*), 2, 8–10
 - antibodies to, 24, 26
 - detection in autopsy specimens, 22
 - germination rate of, 11
 - Gram stain appearance of, 86
 - Sterne strain of, 24
 - virulence of, 9, 10
- gastrointestinal, 12, 19–20, 22
- history of, 1–3
 - in the United States, 3–4
- incubation period of, 8, 14
- infection control precautions for, 228
- inhalational (systemic), 4, 14–24
 - diagnosis of, 23
 - differentiated from ricin intoxication, 212, 213
 - differentiated from tularemia, 86
 - length of terminal episodes in, 15, 17
 - treatment of, 25–28
 - widened mediastinum associated with, 14, 86, 218
- laboratory diagnosis of, 23, 24
- late-stage, 13
- mortality causes in, 12–13, 22, 24
- mortality rates in, 4
- noncontagious nature of, 29
- oral-pharyngeal, 12
- pathogenesis of, 10–13
- postexposure prophylaxis against, 7–8, 25, 227
 - cost of, 242–243, 245, 256
- septicemic, 23
- strains
 - Ames, 8–9, 836, 6
 - Sterne, 9, 24
 - Sterne 34F2, 7

Anthrax, (*cont.*)

- treatment of, 25–28, 227
 - inefficacy of, 26–27, 28
- virulence factors of, 13
 - AnlO, 11
 - AtxA, 11
 - edema factor (EF), 9, 10, 11
 - laboratory tests for, 24
 - lethal factor (LT), 9, 10, 11–12, 13
 - protective antigen (PA), 9, 10, 11, 24–25
- Anthrax Investigation Board, 3
- Anthrax Prevention Act, 3
- Anthrax vaccines/vaccination, 3, 4, 24–25, 221, 224
- Antibiotic prophylaxis, against biological agents, 220–221
 - against anthrax, 7–8, 25, 227
 - cost of, 242–243, 245, 256
 - against plague, 57–60
- Antibiotic resistance
 - in *Burkholderia pseudomallei*, 104, 105, 124
 - in *Francisella tularensis*, 71
 - in *Yersinia pestis*, 56
- Antibiotics, pre-bioterrorist attack distribution of, 246–247
- Antibiotic therapy
 - for anthrax, 25, 26, 27, 28
 - for plague, 55–57
 - for tularemia, 84
- Anticonvulsants, as anthrax treatment, 25
- Anti-inflammatory drugs, as anthrax treatment, 25
- Anti-Terrorism Act of 1996, 39
- Anxiety, bioterrorism-related, 232–233
- Apoptosis, *Francisella tularensis*-induced, 74
- Arenaviruses, 169, 170
 - animal reservoirs for, 170, 177
 - clinical features of, 176
 - epidemiology of, 177–179
 - transmission of, 170, 177
 - treatment of, 181
- Arms Textile Mill, New Hampshire, 4
- Arthralgia, bubonic plague-related, 44
- Assassinations, ricin use in, 205, 206–208, 211
- Aum Shinrikyo, 7, 172, 195
- Autopsy findings
 - in anthrax victims, 21–22, 29
 - in plague victims, 53
 - in tularemia victims, 74–75, 82–83, 90
- Azithromycin, as glanders treatment, 105
- Aztreonam, as plague treatment, 55–56
- Babinski sign, in anthrax, 18–19
- Bacillus anthracis*, 2, 8–10. *See also* Anthrax
 - antibodies to, 24, 26
 - detection in autopsy specimens, 22
 - germination rate of, 11

- Bacillus anthracis* (*cont.*)
 Gram stain appearance of, 86
 spores of, in cadavers, 29
 virulence of, 9, 10
- Bacillus mallei*, 101
- Bacillus pseudomallei*, 101
- Bacillus subtilis*, 26
- Bacteremia
 anthrax-related, 13
 melioidosis-related, 114–115
 tularemia-related, 74
- Bathing, as decontamination method, 224–225
- BBC Television, 157
- Beavers, as tularemia reservoir, 78
- Bell, John, 2–3
- Bestatin, 11
- Beta-lactam antibiotics
 bacterial resistance to, 105
 as melioidosis treatment, 124, 125
- Biological agents, as bioterrorism weapons. *See also*
 specific biological agents
 bans on, 6, 206
 Centers for Disease Control and Prevention classification of
 Category A, 210, 220, 227
 Category B, 118, 119, 210, 220
 Category C, 210, 220
 potential of, 169
- Biological and Toxin Weapons Convention, 38–39, 206
- Biological Weapons Act of 1989, 39
- Biosafety Level -2 procedures, for tularemia specimen handling, 90
- Biosafety Level -3 procedures, for tularemia specimen handling, 90
- Biosafety levels, 231
- Bioterrorism attacks
 economics of planning and preparation for
 for anthrax attacks, 242–244, 245, 256
 calculation of the number of casualties averted, 249–254
 calculation of the value of casualties averted, 254–255
 cost of deploying interventions, 239, 240
 mathematical models in, 240, 249–254
 for pandemic influenza preparations, 241–242, 243, 255
 for postevent medical interventions, 245–246
 for pre-event medical interventions, 245–247
 for pre-event protective interventions, 239, 240, 241
 for preventive preattack interventions, 245–246, 247
 probability of bioterrorist attacks and, 240, 255–256
 realistic expectations in, 253–254
- Bioterrorism attacks (*cont.*)
 selection of interventions for funding, 248–249
 for specific categories of interventions, 244–248
 epidemiologic clues to, 218–219
 response guidelines for health care workers, 217–236
 algorithmic approach of, 217–218, 224
 chemical self-protection, 219, 220–221
 disinfection or decontamination, 224–226
 epidemiological investigation, 232–233
 immunologic self-protection, 219, 221–224
 “index of suspicion,” 218–219
 infection control, 228–229
 notification of authorities, 229–232
 physical self-protection, 219, 220
 primary assessment, 224
 proficiency level, 233–234
 prompt provision of therapy, 226–228
 secondary assessment (diagnosis), 226
 self-protection, 219–224
- BioWatch program, 54, 157
- Birds, as hemorrhagic fever virus reservoirs, 170
- “Black box” syndrome, 253
- Black Death, 37
- Bleach, as environmental decontaminant, 185–186
- Bordetella bronchiseptica*, 103
- Botulinum toxins, 193
 aerosol dispersion of, 201
 bioassays for, 198–199
 as biological weapons, 194–202
 classification as Category A biological weapon, 210
 history of, 194–195
 type A, 193–194, 196, 197, 200
 therapeutic applications of, 194, 197
 type B, 193–194, 196, 197, 200
 type D, 193–194
 type E, 193–194, 196, 197, 200
 type F, 193–194
 type G, 193–194
- Botulism, 5, 193–204
 clinical features of, 195, 218
 diagnosis of, 195–196
 differential diagnosis of, 198, 199
 etiologic agent (*Clostridium botulinum*) of, 193, 194
 foodborne, 194, 195, 196, 198
 history of, 194–195
 infant, 194, 196, 200
 infection control precautions for, 228
 inhalational, 196–197, 198, 201
 prophylaxis against, 227
 treatment of
 in bioterrorist attacks, 201–202
 economic cost of, 193
 of undetermined etiology, 194
 wound, 194

- Botulism vaccines, 201, 224
 Bradford Rules, 3
 Brauell, Freiderich August, 2
 Brokaw, Tom, 7
 Brown Animal Sanatory Institution, 3
 Brucellosis, 80, 210, 228
 Brucellosis vaccines, 224
 Brudzinski's sign, in anthrax, 18, 19
 Buboes, 43, 44, 45, 46, 50
 aspirates from, 52
 tularemia-related, 81
 Bunyaviridae infections, 169, 170, 172
 epidemiology of, 179–180
 treatment of, 181
Burkholderia mallei, 99, 101. *See also* Glanders
 antibiotic susceptibility of, 104, 105
 characteristics of, 102–103
 ecology and environmental survival of, 104
 genomics of, 105
 taxonomy of, 101–102
 typing systems for, 106
Burkholderia pseudomallei, *See also* Melioidosis
 antibiotic susceptibility of, 104–105
 characteristics of, 102–103
 culture methods for, 120–121
 ecology and environmental survival of, 100, 104
 environmental detection of, 127
 genomics of, 105
 identification of, 122
 taxonomy of, 101–102
 typing systems for, 106
 virulence of, 106–110
Burkholderia thailandensis, 101, 102, 106, 117
 Bush, George, 147, 221

 Cadavers. *See also* Autopsy findings
 as anthrax spore source, 29
 plague-infected, 38
 smallpox transmission via, 153, 155
Caenorhabditis elegans, 117
 Canada
 National Emergency Services Stockpile System, 232
 ricin production in, 206
 Canadian Science Center for Human and Animal
 Health, 231
 Carbapenems, as melioidosis treatment, 104, 105
 Carbon malin, 2
 Castor beans (*Ricinus communis*)
 as ricin source, 205–206, 208, 211
 toxicity of, 210, 211
 as mortality cause, 212
 Castor oil, 206, 208
 Casualties, bioterrorism-related, calculation of, 240,
 249–254
 Cathartics, as ricin intoxication treatment, 213

 Cats, as plague vectors, 55
*CDC Biosafety in Microbiological and Biomedical
 Laboratories Manual* (4th edition), 28
 Cefazolin, as plague treatment, 55–56
 Cefotetan, as plague treatment, 55–56
 Ceftazidime
 as melioidosis treatment, 104, 124–125
 bacterial resistance to, 105
 as plague treatment, 55–56
 Ceftriaxone, as plague treatment, 55
 Centers for Disease Control and Prevention (CDC)
 anthrax bioterrorist attacks investigations by, 4, 8
 Anti-Terrorism Act mandate for, 39
 biological agent classification system
 Category A, 210, 220, 227
 Category B, 118, 119, 210, 220
 Category C, 210, 220
 Bioterrorism Preparedness and Response Program,
 229
 botulism diagnostic criteria of, 195–196
 *CDC Biosafety in Microbiological and Biomedical
 Laboratories Manual* (4th edition), 28
 Emergency Preparedness Resources, 229
 Emergency Response Hotline, 229
 possession of smallpox virus, 156
 smallpox diagnostic algorithm, 151, 152, 154
 smallpox response strategy, 223
 Strategic National Stockpile, 229, 232
 Cephalosporins, third-generation, bacterial resistance
 to, 124
 Cerebrospinal fluid analysis, in plague, 50
 Charcoal-impregnated protective overgarments, 220
 Chemical and Biological Weapons Control and
 Warfare Elimination Act of 1991, 39
 Chemical/Biological Incident Response Team, 231
 Chemical/Biological Rapid Response Team
 (CBRRT), 231
 Chemical Weapons Convention, 206
 Chest pain
 bubonic plague-related, 45
 plague-related, 54
 Chickenpox (varicella), infection control precautions
 for, 155, 228
 Children
 melioidosis in, 113
 parotitis associated with, 115, 120
 plague in, 50–51
 plague prophylaxis in, 60
 plague treatment in, 59
 tularemia treatment in, 87, 88–89
 Chills
 plague-related, 44, 45, 47, 48
 in children, 51
 tularemia-related, 81
 viral hemorrhagic fever-related, 177

- China
 anthrax outbreaks in, 3
 plague outbreaks in, 37
- Chloramphenicol
 as melioidosis treatment, 104, 124, 125–126
 bacterial resistance to, 105
 as plague treatment/prophylaxis, 41, 55, 56, 57, 58
 as tularemia-related meningitis treatment, 87
 as tularemia treatment, 88, 89
- Chlorine, 90
- Chocolate, anthrax-contaminated, 5
- Churchill, Winston, 5
- Chyllus corpuscles, 2
- CIA (Central Intelligence Agency), anthrax bioterrorist attacks investigations of, 8
- Ciprofloxacin
 as anthrax prophylaxis and treatment, 25, 28, 227
 as biological agent treatment, 228
 as plague prophylaxis and treatment, 55, 56, 58, 60, 227
 as tularemia prophylaxis and treatment, 87, 88–89, 90, 227
- Clarithromycin, 84–85
- Clostridium botulinum*, as botulism etiologic agent, 193, 194
- Clostridium difficile* infections, infection control precautions for, 228
- Clothing, protective, 220
 for hemorrhagic fever virus control, 184–185
- Clothing change, as decontamination method, 224–225
- Co-amoxiclav, as melioidosis treatment, 125–126
- Cocaine, 157, 196
- Cold War, 38
- Commonwealth Serum Laboratories, 63
- Communicable Disease Center, anthrax investigations by, 4
- Compound W, 206
- Conjunctiva, *Yersinia pestis* inoculation of, 50
- Conjunctivitis
 plague-related, 54
 tularemia-related, 80, 84
- Constipation, botulism-related, 196, 197
- Contact precautions, in infection control, 228
- Convention on the Prohibition of the Development, Production, and Stockpiling of Bacteriological and Toxin Weapons, 71–72
- Cordon sanitaire*, 61–62
- Coronavirus infections, differentiated from plague, 50
- Co-trimoxazole
 as melioidosis prophylaxis, 127
 as melioidosis treatment, 124, 125–126
- Cough
 anthrax-related, 14, 18
 plague-related, 45, 48, 54
 ricin-related, 211
- Coyotes, as tularemia reservoir, 78
- Crimean-Congo hemorrhagic fever virus
 as biological weapon, 170, 171, 172–173
 clinical features of, 176, 179–180
 geographic distribution of, 174
 treatment of, 182
- CXC chemokines, in melioidosis, 112
- Cyanosis
 anthrax-related, 14, 19, 20, 23
 plague-related, 54
 ricin-related, 211
- Cytokines
 in anthrax, 12–13
 in melioidosis, 112
 in viral hemorrhagic fevers, 177
- “Dark Winter,” 157
- Daschle, Tom, 7
- Deafness, Lassa virus-related, 178
- Decontamination
 guidelines for, 224–226
 for hemorrhagic fever virus control, 185–186
 training in, 233
 for tularemia control, 90
 unnecessary, 225
- Deer, as tularemia reservoir, 78
- “Deer-fly fever.” *See* Tularemia
- Deferescence, 84
- Delayed-type hypersensitivity, in tularemia, 76–77
- Dendritic cells, anthrax-related impairment of, 11–12
- Dengue virus, 170
- Devaine, Casimir Joseph, 2
- Diabetes mellitus
 as glanders risk factor, 110–111
 as melioidosis risk factor, 110, 119–120
 in animal models, 116
- Diagnosis, of biological agents-related illnesses, 226
- Diaphoresis, anthrax-related, 14, 15, 17
- Diarrhea
 botulism-related, 195, 196, 197
 melioidosis-related, 114
 plague-related, 46, 47, 54
 in children, 51
 tularemia-related, 81, 82
 viral hemorrhagic fever-related, 177, 178
- Dimethyl sulfoxide (DMSO), 206, 211
- Diphtheria toxin, 209
- Disaster drills, 233
- Disaster Medical Assistance Teams, 231
- Disinfection. *See also* Decontamination guidelines for, 224–226
- Disseminated intravascular coagulation
 plague-related, 56
 smallpox-related, 150
 viral hemorrhagic fever-related, 177, 178

- Dixon, C. W., 153
- Doxycycline
 as anthrax prophylaxis and treatment, 25, 227
 as biological agent treatment, 228
 as melioidosis treatment, 104, 124, 125–126
 as plague prophylaxis and treatment, 55, 56, 57, 58, 59, 60, 227
 as tularemia prophylaxis and treatment, 88–89, 90, 91, 227
 as tularemia-related meningitis treatment, 87
- Droplet precautions, in infection control, 60–61, 228
- Dryvax[®], 222, 223
- Duckering, Elmhurst, 2
- Dysphagia
 anthrax-related, 19
 botulism-related, 197
- Dyspnea
 anthrax-related, 17, 18
 plague-related, 54
 ricin-related, 211
- Eaton-Lambert myasthenic syndrome, 198, 199
- Ebola virus, 219
 as biological weapon, 170, 171, 172
 classification as Category A biological weapon, 210
 clinical features of, 176
 geographic distribution of, 174
 glycoprotein products of, 177
 infection control precautions for, 228
 post-infection persistence of, 175
 treatment of, 182
- Ebola virus vaccines, 183–184
- Ecchymoses, plague-related, 43–44, 46, 47, 54
- Ectromelia, 148
- Eczema vaccinatum, 159, 160
- Edema
 anthrax-related, 11, 14, 15, 21–22
 pulmonary
 anthrax-related, 12, 13, 21
 plague-related, 50
 ricin-related, 211, 213
- Elastase, 108
- Encephalitis
 melioidosis-related, 114
 postvaccinial, 159
- Encephalomyelitis, melioidosis-related, 114
- Endocarditis, tularemia-related, 81
- Enteric infections, infection control precautions for, 228
- Enterotoxin B
 as Category B biological weapon, 210
 infection control precautions for, 228
- Envelopes, containing biological agents, 225
- Environmental Protection Agency (EPA)
 anthrax bioterrorist attacks investigations conducted by, 8
 BioWatch system of, 54, 157
- Epidemiological investigations, of bioterrorism attacks, 232–233
- Epidemiologic sequence, 232
- Equine encephalitides vaccines, 224
- Erythema nodosum, tularemia-related, 82
- Eschar
 anthrax-related, 14
Yersinia pestis inoculation-related, 45
- Eurich, F. W., 2
- Evidence, of bioterrorist attacks, handling of, 225–226
- Exotoxins, of *Burkholderia pseudomallei*, 107
- Fatigue
 anthrax-related, 14, 15–16
 botulism-related, 197
 ricin-related, 211
- Federal agencies, role in bioterrorism response, 230–232
- Federal Aviation Administration (FAA), 157
- Federal Bureau of Investigation (FBI), 229
 anthrax bioterrorist attacks investigations conducted by, 8
 Hazardous Materials Response Unit, 225
- Federal Coordinating Officer, 230
- Federal Response Plan (FRP), 230–231
- Fever, biological agents-related, 218
 anthrax-related, 14, 15, 17
 glanders-related, 115
 melioidosis-related, 114
 plague-related, 44, 46, 47, 48, 54, 56–57
 in children, 51
 smallpox-related, 149, 155
 tularemia-related, 81, 84
 viral hemorrhagic fever-related, 179
- Filovirus infections, 169, 170, 172, 173
 clinical features of, 175–177
 epidemiology of, 175–177
 incubation period of, 175
 infectiousness of, 185
 treatment of, 181–182
- First responders. *See also* Health care workers
 smallpox vaccination in, 161
- Fish poisoning, 194
- Flagella, of *Burkholderia pseudomallei*, 103, 107, 108–109
- Flagellin, 103, 111
- Flaviviridae, 169, 170
- Fleas, as plague vectors, 55, 57–58, 62
- Flies, as tularemia vectors, 78, 79, 86
- Fluoroquinolones
 as anthrax treatment, 28

- Fluoroquinolones (*cont.*)
 as plague prophylaxis and treatment, 41, 57
 as tularemia treatment, 87
- Fort Detrick, Maryland, 71, 91, 92, 118
- Fort Pitt, Pennsylvania, 156
- Fournier, Jean, 2
- Foxes, as tularemia reservoir, 78
- Francisella tularensis*, 71. *See also* Tularemia
 antibiotic resistance in, 71
 antibodies against, 85
 classification as Category A bioterrorism agent, 72
 host immune responses to
 cellular immune response, 76–77
 humoral immune response, 75–76
 pulmonary immune response, 77–78
 infectivity of, 90
 taxonomy of, 72–73
 virulence of, 73–74
- Francisella tularensis* subspecies *holarctica*, 82
- Fuchs, Christian Joseph, 2
- Gangrene, plague-associated, 56
- Gardeners, tularemia in, 79, 85
- Gas masks, 220
- Gastric lavage, as ricin intoxication treatment, 213
- Gentamicin
 as plague treatment, 55, 56, 57, 59, 227
 as tularemia prophylaxis and treatment, 87, 88, 89, 91, 227
- Georgics* (Virgil), 1
- German Armed Medical Forces Academy, 79
- Germany, biological weapons developed/used by, 4, 117–118
- Glanders, 4
 animal models of, 117
 antibiotic prophylaxis against, 127
 as a biological weapon, 117–118
 classification as Category B biological weapon, 210
 clinical features of, 115–116
 diagnosis of
 clinical diagnosis, 120
 laboratory diagnosis, 122
 etiologic agent (*Burkholderia mallei*) of, 99, 101
 antibiotic susceptibility of, 104, 105
 characteristics of, 102–103
 ecology and environmental survival of, 104
 genomics of, 105
 as glanders etiologic agent, 99, 101
 taxonomy of, 101–102
 typing systems for, 106
 geographic distribution of, 101
 history of, 101
 infection control precautions for, 101, 127, 228
 laboratory-acquired, 116, 120
- Glanders vaccines, 128
- Governors, bioterrorism response resources of, 230
- Granulocyte-colony stimulating factor, as melioidosis treatment, 126, 128
- Granzymes, in melioidosis, 112
- Greenfield, William, 3
- Gross Domestic Product (GDP), 254–255
- Gruinard Island, Scotland, 5, 7
- Guanarito virus, 170, 171, 174, 179
- Guanidine, 200
- Guillain-Barré syndrome, 198
- Haemophilus influenzae*, misidentified as *Francisella tularensis*, 85–86
- Hantaviruses, 172
 classification as Category C biological weapons, 210
- Hantavirus pulmonary syndrome, differentiated from plague, 50
- Hares, as tularemia reservoir, 78
- HAZMAT units, 226
- Headaches
 anthrax-related, 16, 17
 plague-related, 44, 47, 48
 in children, 51
 tularemia-related, 81, 84
- Health Canada, 229
- Health care workers
 bioterrorism response guidelines for, 217–236
 algorithmic approach of, 217–218, 224
 chemical self-protection, 220–221
 disinfection or decontamination, 224–226
 epidemiological investigation, 232–233
 immunologic self-protection, 221–224
 “index of suspicion,” 218–219
 infection control, 228–229
 notification of authorities, 229–232
 physical self-protection, 220
 primary assessment, 224
 proficiency level, 233–234
 prompt provision of therapy, 226–228
 secondary assessment (diagnosis), 226
 self-protection, 219–224
 smallpox vaccination in, 155, 159, 160–161, 221, 222
- Health departments, role in bioterrorism response, 229, 230
- Hemolysin, 108
- Hemoptysis
 plague-related, 54, 218
 tularemia-related, 83
- Hemorrhage
 anthrax-related, 11, 13, 21–22
 viral hemorrhagic fevers-related, 177, 178, 179

- Hemorrhagic fever viruses, 169–191, 219
 agricultural impact of, 170, 173, 179
 animal reservoirs for, 170, 173
 arthropod vectors for, 170, 173
 environmental detection of, 186
 epidemiology of, 173–180
 geographic distribution of, 174
 infection control precautions for, 228
 method of dissemination of, 171, 173
 patient management in, 180–183
 clinical recognition, 180
 laboratory diagnosis, 180–181
 treatment of, 181–183
 prevention of
 with environmental decontamination, 185–186
 with infection control, 184–185
 research regarding, 186
 treatment of, 227
- Hemorrhagic fever virus vaccines, 170, 183–184, 224
- Hepatitis
 Crimean-Congo hemorrhagic fever virus-related, 180
 tularemia-related, 81, 82
- Hitler, Adolf, 5
- Hoaxes, involving biological agents, 8, 39, 225
- Horses, glanders in, 101, 115
- Hospital Infection Control Practices Advisory Committee, 60–61
- Hospitals
 bed capacity of, 231
 decontamination training in, 233
 emergency, for smallpox victims, 155
 emergency management plans of, 233
 infection control measures in, 228–229
 for smallpox, 153, 155
 for tularemia, 89–90
 for viral hemorrhagic fevers, 184–185
 melioidosis transmission in, 127
 smallpox transmission in, 153, 155
- Human immunodeficiency virus (HIV) infection. *See*
also Immunocompromised individuals
 relationship with melioidosis, 110
- Hussein, Saddam, 6
- Hypotension
 anthrax-related, 19, 20
 ricin-related, 211
- Hypoxemia, anthrax-related, 14
- Hypoxia, anthrax-related, 12
- Ileus, botulism-related, 200
- Iliad* (Homer), 1
- Illicit drug trade, 157
- Imipenem, as melioidosis treatment, 125
- Immune suppression, anthrax-related, 11
- Immunocompromised individuals
 melioidosis in, 113
- Immunocompromised individuals (*cont.*)
 plague prophylaxis in, 60
 plague treatment in, 59
 smallpox vaccination in, 159
- Immunotoxins, 214
- Incident Command System (ICS), 229–230
- Incubation periods, of biological agents, 169, 218. *See also* under specific biological agents
- Infection control measures, 228–229
 for anthrax, 208
 for hemorrhagic fever viruses, 184–185
 for melioidosis, 126–128
 for smallpox, 153, 155
 for tularemia, 89–90
- Infectious Disease Society of America, 229
- Influenza, infection control precautions for, 228
- Influenza pandemics, cost of planning and preparation for, 241–242, 243, 255
- Interferon- γ
 in melioidosis, 111
 in tularemia, 76
- Interim Biological Agent Detector System (IBADS™), 54
- Interleukin-2 receptors, in melioidosis, 112
- Interleukin-6, in melioidosis, 112
- Interleukin-8, in melioidosis, 112
- Interleukin-10, in melioidosis, 112
- Interleukin-11, in melioidosis, 112
- Interleukin-12, in melioidosis, 111
- Interleukin-15, in melioidosis, 112
- Interleukin-18, in melioidosis, 112
- Ipecac, as ricin intoxication treatment, 213
- Iraq, biological weapons developed/used by
 anthrax, 6
 botulism, 194–195
 ricin, 206
- Ishii, Shiro, 118
- Isolation
 of chickenpox patients, 155
 definition of, 61
 of measles patients, 155
 of plague patients, 60–61
 of smallpox hospitals, 155
 of smallpox patients, 154
- Japan
 Aum Shinrikyo bioterrorist activities in, 7, 172, 195
 biological weapons developed/used by
 anthrax, 5
 botulism, 194
 glanders, 118
 plague, 38
 tularemia, 71
 by Unit 731, 5, 118, 194

- Johns Hopkins Center for Civilian Biodefense, 229
- Johns Hopkins University Schools of Medicine and Public Health, Working Group on Civilian Biodefense Strategies, 40, 58
- Joint Commission on the Accreditation of Healthcare Organizations (JCAHO), 233
- Joint Task Force for Civil Support, 231
- Junin virus, 170, 172
 - antibodies to, 178–179
 - clinical features of, 178–179
 - geographic distribution of, 174
- Junin virus vaccines, 183
- Kamel, Saddam, 6
- Kazakhstan, smallpox outbreak in, 156–157
- Kernig's sign, in anthrax, 18, 19
- Kikaion, 206
- Koch, Robert, 2
- Kosovo, tularemia outbreak in, 79–80
- Kostov, Vladimir, 207–208
- Kyasanur Forest disease virus, 170
- Laboratories, role in bioterrorism response, 229, 230
- Laboratory diagnostic tests. *See also* Specimen handling
 - for anthrax, 24
 - for botulism, 198–199
 - for plague, 51–53
 - for smallpox, 151–153
 - for tularemia, 85–86
 - for viral hemorrhagic fevers, 180–181
- Laboratory Response Network, 51–52, 151, 230
- “*L'affaire du Jardin des Plantes*”, 100
- Lagomorphs, as tularemia reservoir, 78, 79
- Lassa virus/fever, 170, 171, 172, 219
 - clinical features of, 176, 178
 - geographic distribution of, 174
 - infection control precautions for, 228
 - treatment of, 182, 183
- Lawn mowing, as tularemia risk factor, 79, 85
- Leahy, Patrick, 7
- Lecithinase, 108
- Legionnaire's disease, 82
- Lemmings, as tularemia reservoir, 78
- Letters, contaminated with biological agents, 7, 80, 225
- Leukemoid reactions, plague-related, 53
- Levofloxacin, as anthrax prophylaxis, 25, 27
- Lice, 228
- Lightcycler™, 54
- Lipase, 108
- Lipopolysaccharide (LPS)
 - of *Burkholderia mallei*, 103
 - of *Burkholderia pseudomallei*, 102–103, 104, 106–107, 111
- Listeria monocytogenes*, 110
- Livestock
 - as anthrax reservoirs, 55
 - as Rift Valley fever reservoirs, 179
- London, Great Plague of, 37
- Louisiana Territory, 3
- Lung
 - edema of
 - anthrax-related, 12, 13, 21
 - plague-related, 50
 - ricin-related, 211, 213
 - melioidosis of, 115
 - tularemia of, 74, 75, 77–78
- Lymphadenopathy, tularemia-related, 80, 81
- Lymph nodes
 - in anthrax, 11, 12
 - in plague, 43, 44
 - in ricin poisoning, 211
 - in tularemia, 74–75, 81, 84
- Machupo virus, 170, 171, 172
 - antibodies to, 178–179
 - clinical features of, 178–179
 - geographic distribution of, 174
- Macrophages
 - in inhalation anthrax, 10, 11, 12–13
 - in melioidosis, 109, 111
 - in tularemia, 76
 - in viral hemorrhagic fevers, 177
- Malaise
 - anthrax-related, 15–16, 17
 - plague-related, in children, 51
 - tularemia-related, 84
- Marburg virus, 219
 - as biological weapon, 170, 171, 172
 - clinical features of, 176
 - transmission of, 176
 - clinical features of, 176
 - geographic distribution of, 174
 - glycoprotein products of, 177
 - infection control precautions for, 228
 - post-infection persistence of, 175
- Marine Corps, Chemical/Biological Incident Response Team, 231
- Markov, Georgi, 205, 206–208, 211
- Martha's Vineyard, tularemia outbreaks on, 79, 84–85
- Masks, protective, 220
 - HEPA filter, 228
 - for ricin exposure prevention, 212
 - surgical, 228
 - for viral hemorrhagic fever control, 184–185
- Mass vaccination programs, 221–224
- Mathematical models, for estimation of bioterrorism-related casualties, 240, 249–254
 - deterministic models, 250
 - limitations to, 251–253
 - stochastic models, 251

- Measles, infection control precautions for, 155, 228
- Measles patients, isolation of, 155
- Mediastinitis, anthrax-related, 11
- Mediastinum, anthrax-related widening of, 14, 86, 218
- Medical mass casualty (MASCAL) incidents, 217, 218, 224
- Medications. *See also* names of specific medications
stockpiling of, 246–247, 248
- Melioidosis
animal models of, 111–112, 113, 116–117
antibiotic prophylaxis against, 127
as a biological weapon, 118–119
clinical features of, 112–115, 119–120
diagnosis of, 119–124
clinical diagnosis, 119–120
laboratory diagnosis, 120–124
epidemiology of, 99–101
etiologic agent of (*Burkholderia pseudomallei*), 99
antibiotic susceptibility of, 104–105
characteristics of, 102–103
culture methods for, 120–121
culture of, 120–122
ecology and environmental survival of, 100, 104
environmental detection of, 127
genomics of, 105
identification of, 122
as melioidosis etiologic agent, 99
taxonomy of, 101–102
typing systems for, 106
virulence of, 106–110
genetic susceptibility to, 110
geographic distribution of, 99–100
history of, 99
host immune responses to, 110–112
incubation period of, 101
infection control precautions for, 126–218, 228
laboratory-acquired, 116, 118
localized, 115
natural, endemicity of, 128–129
neurological, 114
septicemic, 106, 114–115
as “the remarkable imitator,” 112
transmission of, 100
nosocomial, 127
secondary, 126–127
treatment for, 124–126
- Melioidosis vaccines, 128
- Meningitis
Lassa virus-related, 178
melioidosis-related, 114
plague-related, 43, 50
in children, 50–51
tularemia-related, 81, 86, 87
- Meningococcal disease, infection control precautions for, 228
- Military, role in bioterrorism response, 231–232
- Military personnel
botulinum vaccinations in, 194
smallpox vaccinations in, 221, 222–223
tularemia vaccinations in, 91–92
- Model State Emergency Health Powers Act, 40, 61
- Mohair, anthrax transmission in, 2
- Molecular diagnosis, of melioidosis, 123–124
- Monkeypox, 148, 151, 217
- Mosquitoes
as hemorrhagic fever virus vectors, 170, 173
as Rift Valley fever vectors, 179
as tularemia vectors, 78, 86
- Mousepox, 148
- Murrain, 1
- Muskrats, as tularemia reservoir, 78
- Myalgia
anthrax-related, 14, 16, 17
plague-related, 44
ricin-related, 211
viral hemorrhagic fever-related, 177
- Myasthenia gravis, 198
- Mycoplasma infections, infection control precautions for, 228
- Myocarditis, postvaccinal, 159
- Narcotic analgesics, contraindication in anthrax patients, 28
- Nasal discharge, anthrax-related, 16–17
- National Disaster Medical System (NDMS), 230–231
- National Emergency Services Stockpile System (Canada), 232
- National Microbiology Laboratory (Canada), 181
- National Notifiable Diseases Surveillance System, 80
- National Pharmaceutical Stockpile (NPS), 58, 59
- National Public Health Response Network, 86
- Native Americans, 156
- Nausea
anthrax-related, 3–4, 19–20
botulism-related, 195, 196, 197
plague-related, 46, 47, 54
ricin-related, 211
tularemia-related, 81, 82
viral hemorrhagic fever-related, 177, 178
- Necrosis
liquefaction, plague-related, 48
ricin-related, 211
tularemia-related, 74–75
viral hemorrhagic fever-related, 177, 179
- Nematode anticoagulant protein c2, recombinant, 182
- Nerve conduction velocity, in botulism, 199

- Neuropathy, cranial, botulism-related, 195, 196
- Neurotoxins, clostridial, 193
- Neutrophils, in tularemia, 76
- New York City, anthrax bioterrorism event in, 233
New York Post, 7
- Norfloxacin, as tularemia treatment, 87
- North Atlantic Treaty Organization (NATO), 4
- Norway, 5
- Ofloxacin, as anthrax prophylaxis, 25
- Omsk hemorrhagic fever virus, 170
- Operation Vegetarian, 5
- Opossums, as tularemia reservoir, 78
- Orthopnea, anthrax-related, 17, 18
- Orthopoxviruses, 148, 151
- Osteomyelitis, tularemia-related, 81
- Oxfloxacin, as plague treatment, 55
- Packages, containing biological agents, 225
- Papules, tularemia-related, 80–81
- Parainfluenza, infection control precautions for, 228
- Paralysis, botulism-related, 195–196, 198, 218
- Parotitis, melioidosis-related, 114, 115, 120
- Pasteur, Louis, 3
- Penicillin, as anthrax treatment, 26–27, 28
- Persian Gulf War, 195
- Pertussis, infection control precautions for, 228
- Petechiae, plague-related, 43–44, 46, 47, 54
- Pharyngitis
 - anthrax-related, 16–17
 - plague-related, 50, 54
 - tularemia-related, 81, 84
 - viral hemorrhagic fevers-related, 178
- Piperacillin, as melioidosis treatment, 104
- Plague, 37–70
 - anthrax epidemics described as, 1
 - as a biological weapon, 38–64
 - classification as Category A biological weapon, 210
 - countermeasures to, 39–40
 - history of, 38–39
 - preparedness and response to, 40–41
 - research regarding, 63–64
 - simulations of, 40–41
 - as Black Death, 37
 - bubonic, 37–38, 44–46, 50
 - in children, 50–51
 - in children, 50–51, 59
 - diagnosis of, 51–55
 - in bioterrorist attacks (aerosol release), 53–55
 - laboratory diagnosis, 51–53
 - etiologic agent of (*Yersinia pestis*), 37–38, 41–44
 - antibiotic resistance in, 56
 - antibodies to, 52–53
 - biological agent classification of, 39
- Plague (*cont.*)
 - etiologic agent of (*Yersinia pestis*) (*cont.*)
 - detection in the environment, 53–55
 - federal regulations regarding transfer of, 39–40
 - general characteristics of, 41–42
 - ingestion of, 50
 - laboratory tests for identification of, 51–53
 - molecular genetics of, 42
 - pathogenicity of, 42–44
 - virulence factors of, 42–43
 - flea-borne, 55, 57–58, 62
 - hemoptysis associated with, 218
 - history of, 37–38
 - infection control precautions for, 60–62
 - mortality rate in, 55
 - ocular, 50
 - pandemics of, 37–38
 - pharyngeal, 50, 54
 - pneumonic, 37–38, 48–50
 - differentiated from tularemia, 86
 - incubation period for, 48
 - infection control precautions for, 228
 - isolation of patients with, 60–61
 - during pregnancy, 51, 59
 - prevention of, 62
 - prophylaxis against, 227
 - septicemic, 46–47
 - treatment of, 55–60, 227
 - in bioterrorism events, 58–60
 - in children, 59
 - in immunocompromised individuals, 59
 - in naturally-occurring plague, 55–57
 - postexposure prophylaxis, 57–58, 227
 - pre-exposure prophylaxis, 59
 - during pregnancy, 59
- Plague vaccines, 63, 64, 223, 224
- Plasmids, of *Bacillus anthracis*, 9–10
- Pleural effusions
 - anthrax-related, 27
 - plague-related, 50
 - tularemia-related, 83
- Pleuritis, plague-related, 43
- Pneumococci, infection control precautions for, 228
- Pneumonia
 - “blood-borne,” 114
 - differentiated from ricin intoxication, 212, 213
 - melioidosis-related, 114, 115, 120
 - plague-related, 44, 47, 48–50, 57
 - in children, 50–51
 - tularemia-related, 75, 81, 82–83
- Pneumonitis, plague-related, 43
- Poliomyelitis, epidemics of, 202
- Pollender, Franz Aloys Antoine, 2
- Polymerase chain reaction (PCR)
 - for plague diagnosis, 53, 54–55

- Polymerase chain reaction (PCR) (*cont.*)
 for ricin poisoning diagnosis, 212
 for smallpox diagnosis, 151, 154, 157, 158, 162
 for tularemia diagnosis, 86
- Polymerase chain reaction (PCR)-based BioWatch
 detection system, 54, 157
- Pontiac's Rebellion, 156
- Postal system, anthrax dispersion through, 7, 80, 225
- Postal workers, anthrax in, 7, 8
- Post offices, chemical and biological agent sensors in,
 213
- Pregnancy
 plague during, 51, 59
 plague prophylaxis during, 60
 plague treatment during, 59
 tularemia treatment during, 89
- Primates, as hemorrhagic fever virus reservoirs, 170
- Procalcitonin, in melioidosis, 112
- Protease, 108
- Protection, against biological agents. *See also*
 Decontamination; Disinfection; Vaccination
 for bioterrorism attack responders, 219–224
 chemical protection, 219, 220–221
 immunologic protection, 219, 221–224
 physical protection, 219, 220
 masks, 220
 HEPA filter, 228
 for ricin exposure prevention, 212
 surgical, 228
 for viral hemorrhagic fever control, 184–185
 protective clothing, 220
 for hemorrhagic fever virus control, 184–185
- Proteus mirabilis*, 103
- Protozoa, role in tularemia transmission, 78
- Pseudomonas*
Burkholderia mallei misidentified as, 120
Burkholderia pseudomallei misidentified as, 120
Pseudomonas aeruginosa, 103
- Psychological effects, of bioterrorist attacks, 232–233
- Public health laboratories, role in bioterrorism
 response, 229, 230
- Pustules, anthrax-related, 14
- Pyridostigmine bromide, 220
- Q fever
 as Category B biological weapon, 210
 infection control precautions for, 228
- Q fever vaccine, 224
- Quarantine
 definition of, 61
 as plague response, 61–62
- “Rabbit fever.” *See* Tularemia
- Rabbitpox, 148
- Rabbits, as tularemia reservoir, 78, 79, 80, 82
- “Ragpickers’ disease,” 2–3
- Rainfall, as melioidosis risk factor, 118–120
- Rales, anthrax-related, 18
- Rashes
 plague-related, 45
 smallpox-related, 148, 149, 150, 151, 155
 tularemia-related, 82
 viral hemorrhagic fever-related, 177
- Rayer, Pierre Francoise, 2
- Renal disease, as melioidosis risk factor, 110
- Renal dysfunction
 anthrax-related, 27–28
 melioidosis-related, 114
 tularemia-related, 81–82
- Renal failure
 anthrax-related, 20
 Crimean-Congo hemorrhagic fever virus-related,
 180
 tularemia-related, 81–82
- Respiratory Droplet Precautions, 60–61, 228
- Respiratory syncytial virus, infection control precau-
 tions for, 228
- Rhabdomyolysis, tularemia-related, 81
- Rhamnolipid, of *Burkholderia pseudomallei*, 107
- Ribavirin
 contraindication during pregnancy, 181
 as viral hemorrhagic fever treatment, 172, 181,
 182, 183, 227
- Ribosome inactivating proteins, type 2, 209
- Ricin, 205–216
 administration routes for, 205, 206–207, 211
 implication for treatment, 213
 as a biological weapon, 205, 206–208, 210–211
 action mechanism of, 209
 classification as Category B biological weapon,
 210
 characteristics of, 208–209
 clinical features of, 211–212
 diagnosis of, 212
 differential diagnosis of, 212, 213
 environmental detection of, 213–214
 formulations of, 209
 history of, 205–206
 infection control precautions for, 228
 medical use of, 214
 toxicity of, 209–210
 treatment of, 212–213
 use in political assassinations, 205, 206–208,
 211
- Ricinus communis* (castor bean), as ricin source,
 205–206, 208
 toxicity of, 210, 211
 as mortality cause, 212
- Ricin vaccines, 214, 224
- Rifampin
 as anthrax treatment, 28
 as plague treatment, 55–56

- Rift Valley fever virus
 as biological weapon, 170, 171, 172, 173
 clinical features of, 176
 geographic distribution of, 174
 transmission of, 170, 173, 179
- Rift Valley fever virus vaccines, 183
- Rodents
 as hemorrhagic fever virus reservoirs, 170
 as plague reservoirs, 55
 as tularemia reservoirs, 78, 79–80
- Ruggedized Advanced Pathogen Identification Device (RAPID™), 54
- Sabia virus, 173
 as biological weapon, 170, 171
 clinical features of, 179
 geographic distribution of, 174
- Sarin, 195
- SARS (severe acute respiratory syndrome), 217
 economic impact of, 254
- Scabies, 228
- Seizures, anthrax-related, 18
- Self-decontamination, 224–225
- Senate Hart Building, anthrax contamination of, 7–8
- Sepsis
 plague-related, 46–47, 50, 56
 in children, 51
 tularemia-related, 81
- September 11, 2001, 7–8, 147, 158
- Septicemia
 anthrax-related, 11, 12, 23
 melioidosis-related, 114–115, 119–120
 plague-related, in children, 50–51
- Severe acute respiratory syndrome (SARS), 217
 economic impact of, 254
- Shiga toxin, 209
- Shock
 anthrax-related, 13, 14
 plague-related, 46
- Siderophores, 108
- Sin Nombre virus, 170
- Sinusitis, botulism-related, 196
- Skin infections. *See also* Rashes; Ulcers, cutaneous
 infection control precautions for, 228
 melioidosis-related, 114, 115
- Smallpox, 147–167
 as a biological weapon, 147, 155–158
 classification as Category A biological weapon, 210
 history of, 155–156
 models of, 253
 prevention of, 158–161
 clinical features of, 149–150
 diagnosis of, 151–153
 as disfigurement cause, 155
 epidemiology of, 153–154
- Smallpox (*cont.*)
 etiologic agent for (variola virus), 147–148, 155, 162
 exanthem associated with, 218
 global eradication of, 222
 hemorrhagic, 149, 150
 immunity to, 149
 infection control precautions for, 154–155, 228
 legal stockpiles of, 156, 162
 mortality rate in, 149, 150
 pathogenesis of, 148–149
 patient management in, 154–155
 physical protection against, 220
 prophylaxis against, 227
 transmission of, 153, 154
 in hospitals, 153, 155
 treatment of, 227
 vaccine-modified, 149
 virology of, 147–148
- “Smallpox 2002,” 157
- Smallpox vaccination
 complications of, 159, 222, 223
 in health care workers, 155, 159, 160–161, 221, 222
 mass programs
 surveillance and containment (“ring”) strategy of, 153–154, 223
 U. S. policy for, 159–161
 mass vaccination programs, 221–223
 of patients’ contacts, 154
- Smallpox Vaccine Injury Compensation Program, 223
- Smallpox vaccines, 147, 224
 Dryvax®, 222, 223
 stockpiles of, 158
 vaccinia-based, 162
- Snakes, as tularemia reservoir, 78
- Soci t  de Biologie*, 2
- Soft-tissue infections, melioidosis-related, 114, 115
- Soman, pre-exposure prophylaxis against, 220
- Sore throat. *See* Pharyngitis
- South Africa, 7
- Soviet Union
 anthrax outbreaks in, 6, 21
 biological weapons developed/used by
 anthrax, 6
 botulism, 194
 glanders, 118
 plague, 38, 39
 smallpox, 156
 tularemia, 71
 viral hemorrhagic fevers, 172
- Biopreparat, 118
- Specimen handling
 of hemorrhagic fever virus specimens, 180, 181, 185
 of plague specimens, 53
 of smallpox specimens, 151, 153
 of tularemia specimens, 90

- Spores, of *Bacillus anthracis*, 4, 8, 10, 12
- Standard Precautions, 228
for plague control, 60, 61
for tularemia control, 90
- Staphylococcus enterotoxin B* (SEB)
classification as Category B biological weapon, 210
infection control precautions for, 228
- Steam sterilization, for hemorrhagic fever virus control, 185–186
- Stillmark, Hermann, 206
- Stimulants, as anthrax treatment, 25
- Stone, Silas, 3–4
- Strategic National Stockpile, 202, 229, 232
- Streptococci, group A, infection control precautions for, 228
- Streptomycin
as plague treatment, 55, 56, 57
as tularemia prophylaxis, 91
as tularemia treatment, 86–87, 88
- Sudden death, anthrax-related, 13
- Sulfonamides, as plague treatment, 41
- Sverdlovsk, Russia, anthrax outbreak in, 6, 21
- Sympathetic blockade, as plague treatment, 56
- Systemic inflammatory response syndrome (SIRS), 84
- Tachycardia
anthrax-related, 20, 23
plague-related, 48
- Tachypnea, plague-related, 54
- Tetanospasmin, 193
- Tetracycline
as plague prophylaxis, 57
as plague treatment, 41, 55, 56
as tularemia prophylaxis, 90
as tularemia treatment, 87
- Textile industry workers, anthrax in, 2–3, 4
- Thoracentesis, as inhalational anthrax treatment, 27–28
- Threats, involving biological agents, 8, 39, 225
- Thrombosis, anthrax-related, 12
- Ticks
as Crimean-Congo hemorrhagic fever virus vectors, 170, 179
as hemorrhagic fever virus vectors, 170
as tularemia vectors, 78, 79, 86
- T-2 intoxication, infection control precautions for, 228
- TOPOFF I and II, 40–41
- Trent, William, 156
- Triaging, of bioterrorism victims, 246
- Trimethoprim-sulfamethoxazole. *See also*
Co-trimoxazole as plague treatment, 55, 56
- Trovaflaxacin, as plague treatment, 55
- Tuberculosis
infection control precautions for, 228
miliary, 74
multidrug-resistant, 210
- Tularemia, 71–98
antibiotic prophylaxis against, 90–91, 227
antibodies against, 75–76
as biological weapon, 6, 83–84
classification as Category A biological weapon, 72
history of, 71–72
treatment of, 88–89
clinical manifestations of, 80–84
complications of, 84
diagnosis of, 84–86
endemic, 85
treatment of, 86–87
epidemiology of, 78–80
etiologic agent of (*Francisella tularensis*), 71
antibiotic resistance in, 71
antibodies against, 85
cellular immune response to, 76–77
humoral immune response to, 75–76
infectivity of, 90
pulmonary immune response to, 77–78
taxonomy of, 72–73
virulence of, 73–74
glandular, 80, 81, 84
infection control precautions for, 228
inhalational, 80
nonpneumonic, 80–82
ocular, 84
oculoglandular, 80, 81, 84
oropharyngeal, 80
pathophysiology of, 74–75
pharyngeal, 84
pneumonic, 79, 82–83, 82–85
treatment of, 86–89
in bioterrorist attacks, 88–89
in children, 88–89
during pregnancy, 89
typhoidal, 81–82, 83–84, 91
ulceroglandular, 80, 84
waterborne outbreaks of, 78, 79
control of, 90
- Tularemia vaccines, 76, 77–78, 91–92, 224
- Tumor necrosis factor- α , 76, 112
- Tumor necrosis factor- γ , 112
- Tutu, Desmond, 7
- Ulcers, cutaneous, tularemia-related, 74, 80–81, 84
- Unit 731, 5, 118, 194
- United Kingdom, biological weapons developed/used by
anthrax, 5
ricin, 206
- United States
biological weapons developed/used by
anthrax, 5–6

- United States (*cont.*)
 biological weapons developed/used by (*cont.*)
 botulinum toxin, 5–6, 194
 plague, 39
 ricin, 206
 tularemia, 71–72
 viral hemorrhagic fevers, 172
 plague in, 37, 38
- United States Army. *See also* Military; Military personnel
 anthrax vaccine development by, 24–25
- United States Army Medical Research Institute of Infectious Diseases, 91, 92, 229, 231, 233
- United States Department of Defense, smallpox vaccination program, 222–223
- United States Department of Health and Human Services, 230–231
- United States Department of Homeland Security
 BioWatch detection system, 54, 157
 Office of Emergency Response, 230–231
- United States Northern Command, 231–232
- United States Postal Service, 8, 80, 213
- Vaccination. *See also* specific types of vaccines
 mass programs, 221–224
 prior to bioterrorist attacks, 246, 248–249
- Vaccinia-containing smallpox vaccines, 222
- Vaccinia immune globulin, 147
- Vaccinia virus, 148, 151
- Van Rensberg, Schalk, 7
- Varicella (chickenpox), infection control precautions for, 155, 228
- Variolation, 156
- Variola virus, 148–149, 155. *See also* Smallpox
 environmental detection of, 162
- Vesicular stomatitis virus (VSV), 183–184
- “Vietnamese Time Bomb,” 100
- Vietnam War, 118
- Viral hemorrhagic fevers. *See* Hemorrhagic fever viruses
- Voles, as tularemia reservoir, 78
- Vomiting
 anthrax-related, 3–4, 14, 19–20
 botulism-related, 195, 197
 plague-related, 45, 46, 47, 54
 in children, 51
 ricin-related, 211
 tularemia-related, 82
 viral hemorrhagic fever-related, 177, 178
- Von Rosen, Otto Karl, 5
- Wakamatsu, Yujiro, 118
- “Walking wounded,” 246
- Washington, George, 156
- Waterborne diseases (*cont.*)
 melioidosis, 100, 104, 118, 119–120
 tularemia, 90
- Water supplies
 ricin contamination of, 211
 tularemia contamination of, 90
- Weapons of Mass Destruction-Civil Support teams, 230
- “Weedwhacking,” as tularemia risk factor, 79
- Weight loss, melioidosis-related, 114, 115
- West Nile virus, 217
- Wool, anthrax transmission in, 2–3, 4
- Woolsorters’ disease, 2–3
- Working Group on Civilian Biodefense, 88–89, 90
- World Health Organization (WHO)
 biological warfare committee, 38
 plague prevention and control recommendations, 62
 smallpox vaccination recommendations, 153
 tularemia bioterrorist attack report, 72
- World Trade Center. *See also* September 11, 2001
 1993 terrorist attack on, 39
- World War I, biological weapon use during, 4–5, 117–118
- World War II, biological weapon use during, 5, 38, 194
- “Worried well,” 246
- “Worst case” scenario, of bioterrorist attacks, 252–253
- X-rays, chest
 in anthrax, 14–15, 23
 in melioidosis, 114
 in plague, 48–49, 50, 52
- Yellow fever vaccines, 172, 223–224
- Yellow fever virus
 as biological weapon, 170, 172
 as Category C biological weapon, 210
- Yersinia enterocolitica*, 42
- Yersinia pestis*, 37–38, 41–44
- Yersinia pestis*, 37–38, 41–44. *See also* Plague
 antibiotic resistance in, 56
 antibodies to, 52–53
 biological agent classification of, 39
 detection in the environment, 53–55
 federal regulations regarding transfer of, 39–40
 general characteristics of, 41–42
 ingestion of, 50
 laboratory tests for identification of, 51–53
 molecular genetics of, 42
 pathogenicity of, 42–44
 virulence factors of, 42–43
- Yersinia pseudotuberculosis*, 42
- Zaire, Ebola virus outbreak in, 172
- Zimbabwe, anthrax outbreak in, 3